Cancers, Aifa Approves First Personalized Therapy Against Particular Type Breast Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.6 Articles
6 Articles
Il Tempo
Roma, 11 Sep. (Adnkronos Salute) - Aifa, Italian Agency of the drug, approved the refundability of inavolisib in combination with palbocyclib and fulvestrant, for the treatment of patients with locally advanced or metastatic endocrine cancer resistant, hormonal receptor positive (Hr+), Her2-negative and mutation of the Pik3Ca gene. It announces in a note Roche, explaining that the approval also makes available in Italy a new therapeutic opportun…
(Adnkronos) • • Aifa, Italian Agency of the drug, approved the refundability of inavolisib in combination with palmocyclib and fulvestrant, for the treatment of patients with locally advanced or metastatic endocrine cancer resistant, hormonal receptor positive (Hr+), Her2-negative and mutation of the Pik3Ca gene. It announces in a note Roche, explaining that the approval makes [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
